Valneva SE (VLA) - Total Liabilities
Based on the latest financial reports, Valneva SE (VLA) has total liabilities worth €295.31 Million EUR (≈ $345.25 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Valneva SE - Total Liabilities Trend (2005–2025)
This chart illustrates how Valneva SE's total liabilities have evolved over time, based on quarterly financial data. Explore VLA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Valneva SE Competitors by Total Liabilities
The table below lists competitors of Valneva SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sohu.Com Inc
NASDAQ:SOHU
|
USA | $357.98 Million |
|
Eurocharm Holdings Co Ltd
TW:5288
|
Taiwan | NT$2.03 Billion |
|
Wilson Bayly Holmes Ovcon Ltd
JSE:WBO
|
South Africa | ZAC9.51 Billion |
|
Shinhan Alpha REIT Co Ltd
KO:293940
|
Korea | ₩2.33 Trillion |
|
Dnake Xiamen Intelligent Technology
SHE:300884
|
China | CN¥473.61 Million |
|
Dare Technology Co Ltd
SHE:000910
|
China | CN¥2.32 Billion |
|
China Man-Made Fiber Corp
TW:1718
|
Taiwan | NT$929.48 Billion |
|
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636
|
China | CN¥927.61 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Valneva SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VLA total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valneva SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valneva SE (2005–2025)
The table below shows the annual total liabilities of Valneva SE from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €292.67 Million ≈ $342.16 Million |
-8.19% |
| 2024-12-31 | €318.78 Million ≈ $372.69 Million |
-3.93% |
| 2023-12-31 | €331.81 Million ≈ $387.93 Million |
-17.37% |
| 2022-12-31 | €401.55 Million ≈ $469.45 Million |
-37.92% |
| 2021-12-31 | €646.77 Million ≈ $756.14 Million |
+73.98% |
| 2020-12-31 | €371.74 Million ≈ $434.61 Million |
+186.90% |
| 2019-12-31 | €129.57 Million ≈ $151.48 Million |
+49.41% |
| 2018-12-31 | €86.72 Million ≈ $101.39 Million |
-10.30% |
| 2017-12-31 | €96.67 Million ≈ $113.02 Million |
-9.51% |
| 2016-12-31 | €106.83 Million ≈ $124.90 Million |
-18.36% |
| 2015-12-31 | €130.85 Million ≈ $152.98 Million |
+26.95% |
| 2014-12-31 | €103.07 Million ≈ $120.50 Million |
-6.54% |
| 2013-12-31 | €110.28 Million ≈ $128.93 Million |
+301.41% |
| 2012-12-31 | €27.47 Million ≈ $32.12 Million |
-15.83% |
| 2011-12-31 | €32.64 Million ≈ $38.16 Million |
-7.31% |
| 2010-12-31 | €35.21 Million ≈ $41.17 Million |
+50.31% |
| 2009-12-31 | €23.43 Million ≈ $27.39 Million |
+67.70% |
| 2008-12-31 | €13.97 Million ≈ $16.33 Million |
+32.10% |
| 2007-12-31 | €10.57 Million ≈ $12.36 Million |
+3.03% |
| 2006-12-31 | €10.26 Million ≈ $12.00 Million |
+4.48% |
| 2005-12-31 | €9.82 Million ≈ $11.48 Million |
-- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more